Clinical proteomics: Discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches-A prostate cancer perspective

Vaccine

Volumn 25, Issue SUPPL. 2, 2007, Pages

  Matharoo Ball, Balwir ^a   Ball, Graham ^a   Rees, Robert ^a  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

Bioinformatics; Biomarker; Mass Spectrometry; Prostate cancer; Proteomics

Indexed keywords

TUMOR MARKER;

BIOASSAY; BIOINFORMATICS; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CLINICAL DECISION MAKING; CLINICAL INDICATOR; DATA ANALYSIS; EXPERIMENTAL MODEL; HUMAN; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT PLANNING; TWO DIMENSIONAL ELECTROPHORESIS; VACCINE PRODUCTION;

ANIMALS; CANCER VACCINES; COMPUTATIONAL BIOLOGY; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 34748864783     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.06.040     Document Type: Review

References (105)

1. http://www.cancerworld.org/mediacentre/Prostate_Cancer_Factsheet.aspx#top
2. Denis L., and Murphy G.P. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72 (1993) 3888-3895
3. Miles A.K., Rogers A., Li G., Seth R., Powe D., McArdle S.E., et al. Identification of a novel prostate cancer-associated tumor antigen. Prostate 67 3 (2007) 274-287
4. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per millilitre. N Engl J Med 350 (2004) 2239-2246
5. Catalona W.J., Smith D.S., Ratliff T.L., Dodds K.M., Coplen D.E., Yuan J.J., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156-1161
6. Etzioni R., Penson D.F., Legler J.M., di Tommaso D., Boer R., Gann P.H., et al. Overdiagnosis due to prostate-specific antigen lessons from U.S. prostate cancer incidence trends. J Natl Cancer 94 13 (2002) 981-990
7. Bradley E.B., Bissonette E.A., and Theodorescu D. Determinants of quality of life and voiding function of patients treated with radical prostectomy or permanent brachytherapy for prostate cancer. BJU Int 94 7 (2004) 1003-1009
8. Ichikawa T., Suzuki H., Ueda T., Komiya A., Imamoto T., and Kojima S. Hormone treatment for prostate cancer: current issues and future directions. Cancer Chemother Pharmacol 56 (2005) 58-63
9. Qu Y., Adam B.L., Yasui Y., Ward M.D., Cazares L.H., Schellhammer P.F., et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 48 (2002) 1835-1843
10. Feldman A.L., Espina V., Petricoin E.F., Liotta L.A., and Rosenblatt K.P. Use of proteomic patterns to screen for gastrointestinal malignancies. Surgery 135 (2004) 243-247
11. Poon T.C., Yip T.T., Chan A.T., Yip C., Yip V., Mok T.S., et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 49 (2003) 752-760
12. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., and Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48 (2002) 1296-1304
13. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
14. Villanueva J., Philip J., Entenberg D., Chaparro C.A., Tanwar M.K., Holland E.C., et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-ToF mass spectrometry. Anal Chem 76 (2004) 1560-1570
15. Grubb R.L., Calvert V.S., Wulkuhle J.D., Paweletz C.P., Linehan W.M., Phillips J.L., et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 3 11 (2003) 2142-2146
16. Paweletz C.P., Charboneau L., Bichsel V.E., Simone N.L., Chen T., Gillespie J.W., et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20 16 (2001) 1981-1989
17. Chen Y.T., Güre A.O., Tsang S., Stockert E., Jäger E., Knuth A., et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 95 12 (1998) 6919-6923
18. Bradford T.J., Wang X., and Chinnaiyan A.M. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. Urol Oncol 24 3 (2006) 237-242
19. Petricoin E.F., Ornstein D.K., Paweletz C.P., Ardekani A., Hackett P.S., Hitt B.A., et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94 20 (2002) 1576-1578 16
20. Adam B.L., Qu Y., Davis J.W., Ward M.D., Clements M.A., Cazares L.H., et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62 (2002) 3609-3614
21. Aebersold R., and Mann M. Mass spectrometry-based proteomics. Nature 422 (2003) 198-207
22. Clark R.E., Dodi I.A., Hill S.C., Lill J.R., Aubert G., Macintyre A.R., et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98 10 (2001) 2887-2893
23. Bonner P.L., Lill J.R., Hill S., Creaser C.S., and Rees R.C. Electrospray mass spectrometry for the identification of MHC class I-associated peptides expressed on cancer cells. J Immunol Meth 262 1-2 (2002) 5-19
24. Ball G., Mian S., Holding F., Allibone R.O., Lowe J., Ali S., et al. An integrated approach utilising artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 18 (2002) 395-404
25. Mian S., Ball G., Hornbuckle J., Holding F., Carmichael J., Ellis I., et al. A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditions. Cancer Immunol Immunother 53 3 (2004) 256-261
26. Lotze M.T., and Rees R.C. Identifying biomarkers and surrogates of tumors (cancer biometrics): correlation with immunotherapies and immune cells. Cancer Immunol Immunother 53 3 (2004) 256-261
27. Mian S., Ugurel S., Parkinson E., Schlenzka I., Dryden I., Lancashire L., et al. Serum proteomic fingerprinting discrimonates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol. 23 (2005) 5088-5093
28. Matharoo-Ball B., Ratcliffe L., Lancashire L., Ugurel S., Miles A.K., Weston D.J., et al. Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-ToF mass spectrometry/bioinformatic approach. Proteomics 1 (2007) 605-620
29. Clarke W., Zhang Z., and Chan D.W. The application of clinical proteomics to cancer and other diseases. Clin Chem Lab Med 41 12 (2003) 1562-1570
30. Liotta L.A., Espina V., Mehta A.I., Calvert V., Rosenblatt K., Geho D., et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3 4 (2003) 317-325
31. Utleg A.G., Yi E.C., Xie T., Shannon P., White J.T., Goodlett D.R., et al. Proteomic analysis of human prostasomes. Prostate 56 (2003) 150-161
32. Fung K.Y., Glode L.M., Green S., and Duncan M.W. A comprehensive characterization of the peptide and protein constituents of human seminal fluid. Prostate 61 (2004) 171-181
33. M'Koma A.E., Blum D.L., Norris J.L., Koyama T., Billheimer D., Motley S., et al. Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem Biophys Res Commun 353 3 (2007 Feb 16) 829-834
34. Paweletz C.P., Liotta L.A., and Petricoin III E.F. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urology 57 (2001) 160-163
35. Cazares L.H., Adam B.L., Ward M.D., Nasim S., Schellhammer P.F., Semmes O.J., et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 8 (2002) 2541-2552
36. Diaz J.I., Cazares L.H., Corica A., and John S.O. Selective capture of prostatic basal cells and secretory epithelial cells for proteomic and genomic analysis. Urol Oncol 22 (2004) 329-336
37. Lowenthal M.S., Mehta A.I., Frogale K., Bandle R.W., Araujo R.P., Hood B.L., et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 51 (2005) 1933-1945
38. Manning J.C., Seyrek K., Kaltner H., Andre S., Sinowatz F., and Gabius H.J. Glycomic profiling of developmental changes in bovine testis by lectin histochemistry and further analysis of the most prominent alteration on the level of the glycoproteome by lectin blotting and lectin affinity chromatography. Histol Histopathol 19 (2004) 1043-1060
39. Gretzer M.B., Chan D.W., van Rootselaar C.L., Rosenzweig J.M., Dalrymple S., Mangold L.A., et al. Proteomic analysis of dunning prostate cancer cell lines withvariable metastatic potential using SELDI-ToF. Prostate 60 (2004) 325-331
40. Weinschenk T., Gouttefangeas C., Schirle M., Obermayr F., Walter S., Schoor O., et al. Integrated functional genomics approach for the design of patient-individual antitumour vaccines. Cancer Res 62 (2002) 5818-5827
41. Michener C.M., Ardekani A.M., Petricoin III E.F., Liotta L.A., and Kohn E.C. Genomics and proteomics: application of novel technology to early detection and prevention of cancer. Cancer Detect Prev 26 4 (2002) 249-255
42. O'Farrell P.Z., and Gold L.M. Transcription and translation of prereplicative bacteriophage T4 genes in vitro. J Biol Chem 248 15 (1973) 5512-5519
43. Merril C.R., Switzer R.C., and Van Keuren M.L. Trace polypeptides in cellular extracts and human body fluids detected by two-dimensional electrophoresis and a highly sensitive silver stain. Proc Natl Acad Sci USA 76 9 (1979) 4335-4339
44. Patton W.F. A thousand points of light: the application of fluorescence detection technologies to two-dimensional gel electrophoresis and proteomics. Electrophoresis 21 6 (2000) 1123-1144
45. Unlu M., Morgan M.E., and Minden J.S. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18 11 (1997) 2071-2077
46. Ornstein D.K., Gillespie J.W., Paweletz C.P., Duray P.H., Herring J., Vocke C.D., et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21 11 (2000) 2235-2242
47. Best C.J., and Emmert-Buck M.R. Molecular profiling of tissue samples using laser capture microdissection. Expert Rev Mol Diagn 1 1 (2001) 53-60
48. Paweletz C.P., Liotta L.A., and Petricoin III E.F. New technologies for biomarker analysis of prostate cancer progression: laser capture microdissection and tissue proteomics. Urology 57 4 (2001) 160-163
49. Ahram M., Best C.J., Flaig M.J., Gillespie J.W., Leiva I.M., Chuaqui R.F., et al. Proteomic analysis of human prostate cancer. Mol Carcinog 33 1 (2002) 9-15
50. Lexander H., Palmberg C., Hellman U., Auer G., Hellstrom M., Franzen B., et al. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer. Proteomics 6 15 (2006) 4370-4380
51. Lexander H., Franzen B., Hirschberg D., Becker S., Hellstrom M., Bergman T., et al. Differential protein expression in anatomical zones of the prostate. Proteomics 5 10 (2005) 2570-2576
52. Johansson B., Pourian M.R., Chuan Y.C., Byman I., Bergh A., Pang S.T., et al. Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heatshock protein 60 as a marker for prostate malignancy. Prostate 66 12 (2006) 1235-1244
53. Rowland J.G., Robson J.L., Simon W.J., Leung H.Y., and Slabas A.R. Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells. Proteomics 7 1 (2007) 47-63
54. Qin S., Ferdinand A.S., Richie J.P., O'Leary M.P., Mok S.C., and Liu B.C. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics 5 12 (2005) 3183-3192
55. Fountoulakis M., and Gasser R. Proteomic analysis of the cell envelope fraction of Escherichia coli. Amino Acids 24 1-2 (2003) 19-41
56. Gygi S.P., Corthals G.L., Zhang Y., Rochon Y., and Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci USA 97 17 (2000) 9390-9395
57. Washburn M.P., Wolters D., and Yates III J.R. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 19 3 (2001) 242-247
58. Stoeckli M., Chaurand P., Hallahan D.E., and Caprioli R.M. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 7 4 (2001) 493-496
59. Xu B.J., Caprioli R.M., Sanders M.E., and Jensen R.A. Direct analysis of laser capture microdissected cells by MALDI mass spectrometry. J Am Soc Mass Spectrom 13 11 (2002) 1292-1297
60. Zheng Y., Xu Y., Ye B., Lei J., Weinstein M.H., O'Leary M.P., et al. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 98 12 (2003) 2576-2582
61. Cheung P.K., Woolcock B., Adomat H., Sutcliffe M., Bainbridge T.C., Jones E.C., et al. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res 64 17 (2004) 5929-5933
62. Liu A.Y., Zhang H., Sorensen C.M., and Diamond D.L. Analysis of prostate cancer by proteomics using tissue specimens. J Urol 173 1 (2005) 73-78
63. Ornstein D.K., Rayford W., Fusaro V.A., Conrads T.P., Ross S.J., Hitt B.A., et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol 172 (2004) 1302-1305
64. Pan Y.Z., Xiao X.Y., Zhao D., Zhang L., Ji G.Y., Li Y., et al. Application of surface-enhanced laser desorption/ionization time-of-flight-based serum proteomic array technique for the early diagnosis of prostate cancer. Asian J Androl 8 1 (2006) 45-51
65. Malik G., Ward M.D., Gupta S.K., Trosset M.W., Grizzle W.E., Adam B.L., et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 11 3 (2005) 1073-1085
66. Gross M., Top I., Laux I., Katz J., Curran J., Tindell C., et al. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res 13 7 (2007) 1979-1986
67. van den Bemd G.J., Krijgsveld J., Luider T.M., van Rijswijk A.L., Demmers J.A., and Jenster G. Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice. Mol Cell Proteomics 5 10 (2006) 1830-1839
68. Baggerly K.A., Morris J.S., Coombes K.R., Baggerly K.A., Morris J.S., and Coombes K.R. Reproducibility of SELDI-ToF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20 5 (2004) 777-785
69. Lewczuk P., Esselmann H., Groemer T.W., Bibl M., Maler J.M., Steinacker P., et al. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol Psychiatry 55 5 (2004) 524-530
70. Semmes O.J., Feng Z., Adam B.L., Banez L.L., Bigbee W.L., Campos D., et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer. I. Assessment of platform reproducibility. Clin Chem 51 1 (2005) 102-112
71. Grizzle W.E., Adam B.L., Bigbee W.L., Conrads T.P., Carroll C., Feng Z., et al. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis Markers 19 4-5 (2003-2004) 185-195
72. Lam Y.W., Mobley J.A., Evans J.E., Carmody J.F., and Ho S.M. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics 5 11 (2005) 2927-2938
73. Lopez M.F., Mikulskis A., Kuzdzal S., Golenko E., Petricoin E.F., Liotta L.A., et al. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem 53 6 (2007) 1067-1074
74. Robson B. The dragon on the gold: myths and realities for data mining in biomedicine and biotechnology using digital and molecular libraries. J Proteome Res 3 6 (2004) 1113-1119
75. Lisboa P.J., and Taktak A.F.G. The use of artificial neural networks in decision support in cancer: a systematic review. Neural Networks 19 (2006) 408-415
76. Catto J.W.F., Linkens D.A., Abbod M.F., Chen M., Burton J.L., Feeley K.M., et al. Artificial Intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modelling and artificial neural networks. Clin Cancer Res 9 (2003) 4172-4177
77. Wagner M., Naik D.N., Pothen A., Kasukurti S., Devineni R.R., Adam B.L., et al. Computational protein biomarker prediction: a case study for prostate cancer. BMC Bioinf 5 (2004) 26
78. Saidi S., Holland C.M., Kreil D.P., MacKay D.J.C., Charnock-Jones D.S., Print C.G., et al. Independent component analysis of microarray data in the study of endometrial cancer. Oncogene 23 39 (2004) 6677-6683
79. Chu W., Ghahramani Z., Falciani F., and Wild D.L. Biomarker discovery in microarray gene expression data with Gaussian processes. Bioinformatics 21 (2005) 3385-3393 16
80. Menard C., Johann D., Lowenthal M., Muanza T., Sproull M., Ross S., et al. Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res 66 3 (2006) 1844-1850
81. Chen Y.-D., Zheng S., Yu J.-K., and Hu X. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 10 (2004) 8380-8385
82. Lancashire L., Schmid O., Shah H., and Ball G. Classification of bacterial species from proteomic data using combinatorial approaches incorporating artificial neural networks, cluster analysis and principal components analysis. Bioinformatics 21 10 (2005) 2191-2199
83. Khan J., Wei J.S., Ringner M., Saal L.H., Ladanyi M., Westermann F., et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7 (2001) 673-679
84. Wei J.T., Zhang Z., Barnhill S.D., Madyastha K.R., Zhang H., and Oesterling J.E. Understanding artificial neural networks and their application in urology. Urology 52 (1998) 161-172
85. Balls G.R., Sanders G.E., and Palmer-Brown D. Investigating microclimatic influences on ozone injury in clover (Trifolium subterraneum L. cv. Geraldton) using artificial neural networks. New Phytol 132 (1996) 271-280
86. Desilva C.J.S., Choong P.I., and Attikiouzel Y. Artificial neural networks and breast cancer prognosis. Aust Comput J 26 (1994) 78-81
87. Anagnostou T., Remzi M., and Djavan B. Artificial neural networks for decision-making in urologic. Oncol Rev Urol 5 1 (2003) 15-21
88. Tafeit E., and Reibnegger G. Artificial neural networks in laboratory medicine and medical outcome prediction. Clin Chem Lab Med 37 9 (1999) 845-853
89. Reckwitz T., Potter S.R., and Partin A.W. Prediction of locoregional extension and metastatic disease in prostate cancer: a review. World J Urol 18 3 (2000) 165-172
90. Rumelhart D.E., and McClelland J.L. Parallel distribution processing: explorations in the microstructure of cognition, vol. 1: foundations (1986), MIT Press, Cambridge, MA
91. Bishop C.M. Neural networks for pattern recognition (1995), Oxford University Press Inc., New York, NY
92. Lisboa P.J. A review of evidence of health benefit from artificial neural networks in medical intervention. Neural Networks 15 1 (2002) 11-39
93. Asyali M.H., Colak D., Demirkaya O., and Inan M.S. Gene expression profile classification: a review. Curr. Bioinformat. 1 (2006) 55-73
94. Michiels S., Koscielny S., and Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365 (2005) 488-492 2005
95. Sato F., Shimada Y., Selaru F.M., Shibata D., Maeda M., Watanabe G., et al. Prediction of survival in patients with esophageal carcinoma using artificial neural networks. Cancer 103 (2005) 1596-1605
96. Delen D, Walker G, Kadam A. Predicting breast cancer survivability. Artif Intell Med 2005;34(2):113-27.
97. Iversen C., Lancashire L., Waddington M., Forsyth S., and Ball G. Identification of Enterobacter sakazakii from closely related species: the use of artificial neural networks in the analysis of biochemical and 16S rDNA data. BMC Microbiol 6 (2006) 28
98. Michael A., Ball G., Quatan N., Wushishi F., Russell N., Whelan J., et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 11 12 (2005) 4469
99. Stephan C., Cammann H., and Jung K. Artificial neural networks: has the time come for their use in prostate cancer patients?. Nat Clin Pract Urol 2 6 (2005) 262-263
100. Stephan C., Meyer H.A., Kwiatkowski M., Recker F., Cammann H., Loening S.A., et al. A (-5, -7) proPSA based artificial neural network to detect prostate cancer. Eur J Urol 50 5 (2006) 1014-1020
101. Djavan B., Remzi M., Zlotta A., Seitz C., Snow P., and Marberger M. Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 4 (2002) 921-929
102. Naguib R.N., Robinson M.C., Neal D.E., and Hamdy F.C. Neural network analysis of combined conventional and experimental prognostic markers in prostate cancer: a pilot study. Br J Cancer 78 2 (1998) 246-250
103. Mattfeldt T., Kestler H.A., Hautmann R., and Gottfried H.W. Prediction of prostatic cancer progression after radical prostatectomy using artificial neural networks: a feasibilty study. BJU Int 84 (1999) 316-323
104. Crawford E.D., Batuello J.T., Snow P.B., et al. The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate cancer. Cancer 88 9 (2000) 2105-2109
105. Rehman I., Azzouzi A.R., Catto J.W., Allen S., Cross S.S., Feeley K., et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 64 6 (2004) 1238-1243